EVEROLIMUS MSDS PDF

Acute toxicity: oral toxicity (LD50): > mg/kg (mouse), > mg/kg (rat) – toxicity data from the Abbott Vascular MSDS dated January 16, for Everolimus. SAFETY DATA SHEET. (in accordance with Regulation (EU) /). Everolimus. Version: 1. Revision date: 29/06/ Page 1 of. Material Safety Data Sheet. Section 1 – Product and Company Information. Product Name: Everolimus. Cat. Code: tlrl-eve. Company identification: InvivoGen.

Author: Zusar Mugis
Country: Sao Tome and Principe
Language: English (Spanish)
Genre: Sex
Published (Last): 2 August 2012
Pages: 215
PDF File Size: 17.56 Mb
ePub File Size: 19.59 Mb
ISBN: 255-8-72009-612-8
Downloads: 77279
Price: Free* [*Free Regsitration Required]
Uploader: Kazrajinn

Everolimus – DrugBank

Linezolid The risk or severity of adverse effects can be increased when Linezolid is combined with Everolimus. Macitentan The metabolism of Everolimus can be decreased when combined with Macitentan.

Like all tacrolimus analogues, everolimus binds to receptor protein, FKBP Methimazole Eveolimus metabolism of Everolimus can be decreased when combined with Methimazole.

Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Everolimus.

Metreleptin The metabolism of Everolimus can be increased when combined with Metreleptin. Metergoline The serum concentration of Metergoline can be increased when it is combined with Everolimus. Methyltestosterone The metabolism of Everolimus evetolimus be decreased when combined with Methyltestosterone.

Lercanidipine The metabolism of Everolimus can be decreased when combined with Lercanidipine. Icosapent ethyl The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Everolimus.

  EINDWERK INFORMATICA PDF

Nimesulide The metabolism of Everolimus can be decreased when combined with Nimesulide. Cabazitaxel The serum concentration of Everolimus can be increased when it is combined with Cabazitaxel.

Idelalisib The serum concentration of Everolimus can be increased when it is combined with Idelalisib.

Letermovir The serum concentration of Everolimus can be increased when it is combined with Letermovir. Felodipine The serum concentration of Msdd can be increased when it is combined with Felodipine.

Nelarabine The risk or severity of adverse effects can be increased when Nelarabine is combined with Everolimus. Mds The serum concentration of Dolutegravir can be increased when it is combined with Everolimus. Oxazepam The metabolism of Everolimus can be decreased when combined with Oxazepam.

Imidafenacin The metabolism of Everolimus can be decreased when combined with Imidafenacin. Remove contaminated clothing and wash before reuse. Metformin The therapeutic efficacy of Metformin can be decreased when used in combination with Everolimus. Carboplatin The risk or severity of adverse effects can be increased when Carboplatin is combined with Everolimus.

Fluphenazine The serum concentration of Everolimus can be increased when it is combined with Fluphenazine. Interferon alfa-2b The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Everolimus. Nystatin The metabolism of Everolimus can be decreased when combined with Nystatin. Wash thoroughly after handling.

  CONCEVOIR LE TABLEAU DE BORD CAROLINE SELMER PDF

Alfentanil The metabolism of Everolimus can be decreased when combined with Alfentanil. Ardeparin The risk or severity of bleeding can be increased when Ardeparin is combined with Everolimus.

Everolimus

Adverse reactions Some serious adverse reactions associated with Everolimus include non-infection pneumonitis, infections, severe hypersensitivity reactions, angioedema with concomitant use of ACE inhibitors, stomatitis, renal failure, impaired wound healing, metabolic disorders and myelosuppression [10]. Metamizole The risk or severity of myelosuppression can be increased when Metamizole is combined with Everolimus.

Bendroflumethiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Everolimus. Lidoflazine The metabolism of Everolimus can be decreased when combined with Lidoflazine. Cortivazol The risk or severity of adverse effects can be increased when Everolimus is combined with Cortivazol.

Fluperolone The risk or severity of adverse effects can be increased when Everolimus is combined with Fluperolone. Equilenin The metabolism of Everolimus can be decreased when combined with Equilenin. Caroverine The metabolism of Everolimus can be decreased when combined with Caroverine.